Display options
Cite
Aldawsari HM, Singh S, Alhakamy NA, et al. Gum Acacia Functionalized Colloidal Gold Nanoparticles of Letrozole as Biocompatible Drug Delivery Carrier for Treatment of Breast Cancer. Pharmaceutics. 2021;13(10)doi: 10.3390/pharmaceutics13101554.
Aldawsari, H. M., Singh, S., Alhakamy, N. A., Bakhaidar, R. B., Halwani, A. A., & Badr-Eldin, S. M. (2021). Gum Acacia Functionalized Colloidal Gold Nanoparticles of Letrozole as Biocompatible Drug Delivery Carrier for Treatment of Breast Cancer. Pharmaceutics, 13(10), . https://doi.org/10.3390/pharmaceutics13101554
Aldawsari, Hibah M, et al. "Gum Acacia Functionalized Colloidal Gold Nanoparticles of Letrozole as Biocompatible Drug Delivery Carrier for Treatment of Breast Cancer." Pharmaceutics vol. 13,10 (2021). doi: https://doi.org/10.3390/pharmaceutics13101554
Aldawsari HM, Singh S, Alhakamy NA, Bakhaidar RB, Halwani AA, Badr-Eldin SM. Gum Acacia Functionalized Colloidal Gold Nanoparticles of Letrozole as Biocompatible Drug Delivery Carrier for Treatment of Breast Cancer. Pharmaceutics. 2021 Sep 24;13(10). doi: 10.3390/pharmaceutics13101554. PMID: 34683847; PMCID: PMC8538880.
Copy Download .nbib Format: NLM
Share it on

Pharmaceutics. 2021 Sep 24;13(10). doi: 10.3390/pharmaceutics13101554.

Gum Acacia Functionalized Colloidal Gold Nanoparticles of Letrozole as Biocompatible Drug Delivery Carrier for Treatment of Breast Cancer.

Pharmaceutics

Hibah M Aldawsari, Sima Singh, Nabil A Alhakamy, Rana B Bakhaidar, Abdulrahman A Halwani, Shaimaa M Badr-Eldin

Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  2. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  3. IES Institute of Pharmacy, IES University Campus, Bhopal 462044, India.
  4. Mohamed Saeed Tamer Chair for Pharmaceutical Industries, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.

PMID: 34683847 PMCID: PMC8538880 DOI: 10.3390/pharmaceutics13101554

Abstract

The most prevalent malignancy among postmenopausal women is breast cancer. It is one of the leading causes of cancer-related mortality among women. Letrozole (LTZ) is a clinically approved inhibitor for breast cancer in postmenopausal women. However, due to poor aqueous solubility, non-specific binding, unwanted toxicity, and poor blood circulation hampered its clinical applications. To maximize the pharmacological effects and minimize the side effects, inorganic nanoparticles are a good alternative. Due to excellent biocompatibility and minimum cytotoxicity, gold nanoparticles (AuNPs) offer distinct benefits over other metal nanoparticles. Emerging as attractive components, AuNPs and Gum acacia (GA) have been extensively studied as biologically safe nanomaterials for the treatment of cancers. This study reports the synthesis and characterization of GA stabilized gold nanoparticles (GA-AuNPs) of LTZ for breast cancer treatment. The observed particle size of optimized LTZ @ GA-AuNPs was 81.81 ± 4.24 nm in size, 0.286 ± 0.143 of polydispersity index (PDI) and -14.6 ± -0.73 mV zeta potential. The biologically synthesized LTZ @ GA-AuNPs also demonstrated dose-dependent cytotoxicity against the human breast cancer cell line MCF-7, with an inhibitory concentration (IC

Keywords: Gum acacia; biocompatibility; breast cancer; gold nanoparticles; letrozole

References

  1. Drugs. 1998 Dec;56(6):1125-40 - PubMed
  2. Adv Colloid Interface Sci. 2015 May;219:1-9 - PubMed
  3. Mater Sci Eng C Mater Biol Appl. 2021 Oct;129:112384 - PubMed
  4. Ann Oncol. 2014 Oct;25(10):1871-1888 - PubMed
  5. CA Cancer J Clin. 2021 May;71(3):209-249 - PubMed
  6. Int J Clin Pharmacol Ther. 2012 Aug;50(8):557-65 - PubMed
  7. Med Chem. 2021;17(7):750-765 - PubMed
  8. Nat Rev Clin Oncol. 2015 Sep;12(9):541-52 - PubMed
  9. Int J Pharm. 2021 May 1;600:120493 - PubMed
  10. Drug Discov Today. 2021 Jul;26(7):1721-1727 - PubMed
  11. Sci Rep. 2019 May 1;9(1):6754 - PubMed
  12. Nat Commun. 2021 Mar 19;12(1):1786 - PubMed
  13. Int J Biol Macromol. 2017 Nov;104(Pt B):1820-1832 - PubMed
  14. Breast Cancer Res Treat. 2007;105 Suppl 1:7-17 - PubMed
  15. Carbohydr Polym. 2016 Nov 5;152:479-486 - PubMed
  16. Pharm Dev Technol. 2019 Feb;24(2):235-242 - PubMed
  17. Toxicol Sci. 2005 Dec;88(2):412-9 - PubMed
  18. J Clin Oncol. 2014 Oct 10;32(29):3307-29 - PubMed
  19. Curr Med Chem. 2018;25(34):4269-4303 - PubMed
  20. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010 Mar-Apr;2(2):113-29 - PubMed
  21. Pharm Res. 2017 Dec;34(12):2798-2808 - PubMed
  22. Technol Cancer Res Treat. 2019 Jan-Dec;18:1533033819853241 - PubMed
  23. Cancer Cell. 2020 Apr 13;37(4):496-513 - PubMed
  24. Nanomaterials (Basel). 2017 May 27;7(6): - PubMed
  25. Nanomaterials (Basel). 2020 Mar 11;10(3): - PubMed
  26. Pharmacol Rev. 2001 Jun;53(2):283-318 - PubMed
  27. ACS Omega. 2020 May 18;5(21):11935-11945 - PubMed
  28. Methods Mol Biol. 2019;1974:215-221 - PubMed
  29. Int Immunopharmacol. 2020 Jun;83:106417 - PubMed
  30. Biosens Bioelectron. 2019 Jul 15;137:213-221 - PubMed
  31. J Steroid Biochem Mol Biol. 2003 Oct;87(1):35-45 - PubMed

Publication Types

Grant support